Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
GlycoMimetics (GLYC)
NASDAQ:GLYC
GlycoMimetics (GLYC) Stock Price & Analysis
870 Followers
GLYC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.24 - $3.53
Previous Close$0.3
Volume1.12M
Average Volume (3M)4.43M
Market Cap
$19.09M
Enterprise Value-$11.58M
Total Cash (Recent Filing)$31.30M
Total Debt (Recent Filing)$630.83K
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Aug 01, 2024EPS Estimate
-$0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding64,464,412
10 Day Avg. Volume706,986
30 Day Avg. Volume4,428,427
Standard Deviation0.37
R-Squared0.09
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)0.57
Price to Sales (P/S)1658.67
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-1.16K
Enterprise Value/Gross Profit-1.16K
Enterprise Value/Ebitda0.32
Forecast
1Y Price Target
$0.50Price Target Upside86.01% Upside
Rating ConsensusHold
Number of Analyst Covering2
GlycoMimetics News
PremiumCompany Announcements
GlycoMimetics Reports Phase 3 Uproleselan Trial Success
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessUproleselan has demonstrated an extended survival benefit in the Phase III trial, suggesting potential superiority over standard chemotherapy in relapsed or refractory AML.
Financial StabilityThe company has a sufficient cash runway through the next year, which provides stability and time for further development.
Regulatory ApprovalsUproleselan was previously granted Breakthrough Therapy Designation (BTD) from the FDA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML).
Bears Say
Clinical TrialsThe P3 study of uproleselan plus standard-of-care chemo in relapsed/refractory acute myeloid leukemia did not meet its primary endpoint of overall survival.
Financial PerformanceGlycomimetics reported a net loss of $9.08 million for the fourth quarter.
Stock PerformanceShares of GLYC are down approximately 81% following the announcement of the study results.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
GLYC FAQ
What was GlycoMimetics’s price range in the past 12 months?
GlycoMimetics lowest stock price was $0.23 and its highest was $3.53 in the past 12 months.
What is GlycoMimetics’s market cap?
Currently, no data Available
When is GlycoMimetics’s upcoming earnings report date?
GlycoMimetics’s upcoming earnings report date is Aug 01, 2024 which is in 29 days.
How were GlycoMimetics’s earnings last quarter?
GlycoMimetics released its earnings results on May 09, 2024. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.16 by -$0.01.
Is GlycoMimetics overvalued?
According to Wall Street analysts GlycoMimetics’s price is currently Undervalued.
Does GlycoMimetics pay dividends?
GlycoMimetics does not currently pay dividends.
What is GlycoMimetics’s EPS estimate?
GlycoMimetics’s EPS estimate is -$0.17.
How many shares outstanding does GlycoMimetics have?
GlycoMimetics has 64,464,410 shares outstanding.
What happened to GlycoMimetics’s price movement after its last earnings report?
GlycoMimetics reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.16. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of GlycoMimetics?
Currently, no hedge funds are holding shares in GLYC
---
GlycoMimetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.50 (86.01% Upside)
$0.50 (86.01% Upside)
Blogger Sentiment
Bullish
GLYC Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $81.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 10.1%
Last 30 Days ▼ 10.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.98%
12-Months-Change
Fundamentals
Return on Equity
-81.84%
Trailing 12-Months
Asset Growth
-50.37%
Trailing 12-Months
Company Description
GlycoMimetics
GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.
---
GLYC Earnings Call
Q4 2024
0:00 / 0:00
---
GLYC Stock 12 Month Forecast
Average Price Target
$0.50
▲(86.01% Upside)
Technical Analysis
Best Analysts Covering GLYC
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-18.42%
reiterated a buy rating 3 months ago
Copying Roger Song's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -18.42% per trade.
---